Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Mirum Pharmaceuticals, Inc. (MIRM) Tops Q1 EPS by 17c
May 5, 2022 8:12 AM EDTMirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q1 EPS of ($1.17), $0.17 better than the analyst estimate of ($1.34). Revenue for the quarter came in at $12.9 million versus the consensus estimate of $8.46 million.
For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.
... More